Utidelone vs docetaxel for HER2-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial compares utidelone with docetaxel in people with HER2-negative advanced or metastatic breast cancer. It aims to see which treatment works better and is safer for controlling the cancer and helping patients live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a woman age 18 or older and be able to sign consent.
- Your breast cancer must be locally advanced or metastatic, and tests must confirm it is HER2-negative (not HER2-positive).
- Your health should be fairly good for treatment (ECOG 0–1).
- You need at least one spot that doctors can measure on scans, or bone-only spread that can be checked with bone scan, PET, or MRI.
- If you’ve had chemo with a taxane before, it must have been for earlier-stage breast cancer and finished at least 12 months before starting this study; you should not have had chemo for advanced breast cancer before.
- You must have recovered from past treatment side effects to mild levels (grade 1 or less), and you need adequate blood, liver, and kidney function.
- If you can become pregnant, you must use birth control during treatment and for at least 90 days after the last dose; you must not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new chemotherapy combination (utidelone plus capecitabine) versus a standard taxane plus capecitabine for HER2-negative breast cancer. The goal is to see if the new combo works better and has fewer side effects.
This trial tests two targeted drugs, trastuzumab rezetecan and trastuzumab deruxtecan, to see which works better for HER2-positive breast cancer that has spread or cannot be removed by surgery. These drugs target the HER2 protein on cancer cells to slow or stop their growth.
This trial tests a new chemotherapy drug called utidelone, given before surgery for early high-risk or locally advanced breast cancer. The goal is to see if this drug can shrink tumors and improve outcomes. It may be a treatment option for people who meet the specific criteria.
This trial studies whether utidelone combined with bevacizumab can shrink tumors and slow progression in women with advanced HER2-negative breast cancer that has already been treated at least twice. It may help people who have limited options after earlier chemotherapy and/or hormone (endocrine) treatments.
This trial tests if the combination of Utidelone and capecitabine can shrink brain metastases in people with HER2-negative breast cancer. It is designed for those whose cancer has spread to the brain and who have not had many prior treatments.
This trial compares an oral capsule form of the experimental drug Utidelone with the standard injection form, in people with HER2-negative advanced breast cancer. The goal is to see if the capsule works as well as the injection and is safe to use.
Hear when a new Breast Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.